Mutational Analysis of Circulating Tumor Cells from Colorectal Cancer Patients and Correlation with Primary Tumor Tissue

Lyberopoulou, Anna; Aravantinos, Gerasimos; Efstathopoulos, Efstathios P.; Nikiteas, Nikolaos; Bouziotis, Penelope; Isaakidou, Athina; Papalois, Apostolos; Marinos, Evangelos; Gazouli, Maria
April 2015
PLoS ONE;Apr2015, Vol. 10 Issue 4, p1
Academic Journal
Circulating tumor cells (CTCs) provide a non-invasive accessible source of tumor material from patients with cancer. The cellular heterogeneity within CTC populations is of great clinical importance regarding the increasing number of adjuvant treatment options for patients with metastatic carcinomas, in order to eliminate residual disease. Moreover, the molecular profiling of these rare cells might lead to insight on disease progression and therapeutic strategies than simple CTCs counting. In the present study we investigated the feasibility to detect KRAS, BRAF, CD133 and Plastin3 (PLS3) mutations in an enriched CTCs cell suspension from patients with colorectal cancer, with the hypothesis that these genes` mutations are of great importance regarding the generation of CTCs subpopulations. Subsequently, we compared CTCs mutational status with that of the corresponding primary tumor, in order to access the possibility of tumor cells characterization without biopsy. CTCs were detected and isolated from blood drawn from 52 colorectal cancer (CRC) patients using a quantum-dot-labelled magnetic immunoassay method. Mutations were detected by PCR-RFLP or allele-specific PCR and confirmed by direct sequencing. In 52 patients, discordance between primary tumor and CTCs was 5.77% for KRAS, 3.85% for BRAF, 11.54% for CD133 rs3130, 7.69% for CD133 rs2286455 and 11.54% for PLS3 rs6643869 mutations. Our results support that DNA mutational analysis of CTCs may enable non-invasive, specific biomarker diagnostics and expand the scope of personalized medicine for cancer patients.


Related Articles

  • PD-0003COMPARISON OF KRAS MUTATION STATUS BETWEEN PRIMARY TUMORS AND CIRCULATING TUMOR CELLS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC). Kalikaki, Aristea; Politaki, Helen; Tzardi, Maria; Papadimitraki, Elisavet; Mavroudis, Demitris; Souglakos, John; Voutsina, Alexandra; Georgoulias, Vassilis // Annals of Oncology;Jun2013, Vol. 24 Issue suppl_4, piv25 

    No abstract available.

  • KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Dijkstra, J.; Heideman, D.; Meijer, G.; Boers, J.; Hart, N.; Diebold, J.; Hirschmann, A.; Hoefler, G.; Winter, G.; Miltenberger-Miltenyi, G.; Pereira, S.; Richman, S.; Quirke, P.; Rouleau, E.; Guinebretiere, J.; Tejpar, S.; Biesmans, B.; Krieken, J. // Virchows Archiv;Jan2013, Vol. 462 Issue 1, p39 

    KRAS mutation testing is mandatory for patients with metastatic colorectal cancer who are eligible for treatment with an epidermal growth factor receptor targeting agent, since tumors with a mutation are not sensitive to the drug. Several methods for mutation testing are in use and the need for...

  • KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients. GUTIÉRREZ, CRISTINA; RODRIGUEZ, JAVIER; PATIÑO-GARCÍA, ANA; GARCÍA-FONCILLAS, JESÚS; SALGADO, JOSEFA // Oncology Letters;2013, Vol. 6 Issue 5, p1343 

    The present study describes an optimized method for isolating peripheral blood circulating tumor cells (CTCs) and performing KRAS mutation analysis. The approach combines isolation of peripheral blood mononuclear cells and immunomagnetic labeling with CD45 and CD326 human microbeads with KRAS...

  • Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Miyaki, Michiko; Iijima, Takeru; Konishi, Motoko; Sakai, Kimiyo; Ishii, Aki; Yasuno, Masamichi; Hishima, Tsunekazu; Koike, Morio; Shitara, Nobuyuki; Iwama, Takeo; Utsunomiya, Joji; Kuroki, Toshio; Mor, Takeo // Oncogene;5/20/99, Vol. 18 Issue 20, p3098 

    We have previously detected an increased frequency of loss of heterozygosity (LOH) on chromosome 18q during progression of colorectal carcinomas. To clarify the target of 18qLOH, mutation of Smad4 and Smad2 genes was analysed in 176 colorectal tumors with different stages, including liver...

  • Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells. Mologni, Luca; Brussolo, Stefania; Ceccon, Monica; Gambacorti-Passerini, Carlo // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Activation of Wnt signalling due to inability to degrade b-catenin is found in >85% of colorectal cancers. Approximately half of colon cancers express a constitutively active KRAS protein. A significant fraction of patients show both abnormalities. We previously reported that simultaneous...

  • Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Nishikawa, G; Sekine, S; Ogawa, R; Matsubara, A; Mori, T; Taniguchi, H; Kushima, R; Hiraoka, N; Tsuta, K; Tsuda, H; Kanai, Y // British Journal of Cancer;3/5/2013, Vol. 108 Issue 4, p951 

    Background:The molecular basis for the development of appendiceal mucinous tumours, which can be a cause of pseudomyxoma peritonei, remains largely unknown.Methods:Thirty-five appendiceal mucinous neoplasms were analysed for GNAS and KRAS mutations. A functional analysis of mutant GNAS was...

  • Manipulation of nonsense mediated decay identifies gene mutations in colon cancer Cells with microsatellite instability. Ionov, Yurij; Nowak, Norma; Perucho, Manuel; Markowitz, Sanford; Cowell, John K. // Oncogene;1/22/2004, Vol. 23 Issue 3, p639 

    Cancer cells showing microsatellite instability (MSI) demonstrate a high frequency of acquired frameshift mutations that result in the generation of nonsense mutations. RNA transcripts carrying these nonsense mutations are usually targeted for degradation through the nonsense mediated decay...

  • Genetic Lesions during Progression of Hereditary Non-polypous Colorectal Cancer. Shtam, T. A.; Vostryukhina, O. A.; Gulyaev, A. V.; Pozharissky, K. M.; Lantsov, V. A. // Doklady Biochemistry & Biophysics;Mar/Apr2004, Vol. 395 Issue 1-6, p69 

    Presents a study which focused on genetic lesions during progression of hereditary non-polypous colorectal cancer (HNPCC). Description and etiology of HNPCC; Analysis of the genetic changes accumulated in cells of patients with HNPCC syndrome; Information on the hereditary mutation of the disease.

  • The mitochondrial DNA 4,977-bp deletion and its implication in copy number alteration in colorectal cancer. Tao Chen; Jing He; Lijun Shen; Hezhi Fang; Hezhongrong Nie; Tao Jin; Xiaosong Wei; Yijuan Xin; Yulin Jiang; Hongzhi Li; Guorong Chen; Jianxin Lu; Yidong Bai // BMC Medical Genetics;2011, Vol. 12 Issue 1, p1 

    Background: Qualitative and quantitative changes in human mitochondrial DNA (mtDNA) have been implicated in various cancer types. A 4,977 bp deletion in the major arch of the mitochondrial genome is one of the most common mutations associated with a variety of human diseases and aging. Methods:...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics